Tricida, Inc. (TCDA): Price and Financial Metrics

Tricida, Inc. (TCDA): $0.22

-0.01 (-3.95%)

POWR Rating

Component Grades













TCDA Stock Price Chart Interactive Chart >

Price chart for TCDA

TCDA Price/Volume Stats

Current price $0.22 52-week high $13.85
Prev. close $0.23 52-week low $0.19
Day low $0.21 Volume 4,580,100
Day high $0.24 Avg. volume 3,134,446
50-day MA $4.49 Dividend yield N/A
200-day MA $8.54 Market Cap 12.18M

Tricida, Inc. (TCDA) Company Bio

Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.

TCDA Latest News Stream

Event/Time News Detail
Loading, please wait...

TCDA Latest Social Stream

Loading social stream, please wait...

View Full TCDA Social Stream

Latest TCDA News From Around the Web

Below are the latest news stories about TRICIDA INC that investors may wish to consider to help them evaluate TCDA as an investment opportunity.

15 Most Shorted Stocks Right Now

In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inflation and rising rates combine to create an uncertain business environment […]

Yahoo | November 17, 2022

Peninsula drug company Tricida cutting more than half of staff after clinical trial failure

The company earlier this month said it was looking at "strategic alternatives," including a sale in whole or in part.

Yahoo | November 16, 2022

Needham Sticks to Its Hold Rating for Tricida (TCDA)

In a report released today, Serge Belanger from Needham maintained a Hold rating on Tricida (TCDA - Research Report). The company's shares closed yesterday at $0.27.According to TipRanks, Belanger is an analyst with an average return of -4.8% and a 40.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.The analyst consensus on Tricida is currently a Moderate Sell rating.See today’s best-performing stocks on TipRanks >>Based on Tricida's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $28.54 million.

Ryan Adist on TipRanks | November 15, 2022

Tricida Announces Third Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., November 14, 2022--Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives.

Yahoo | November 14, 2022

Peninsula kidney drug company weighs 'strategic alternatives' after clinical trial flop

The nine-year-old company, which once employed 200 people but now has less than 60, is the third in a triumvirate of kidney drug ventures started by a team led by Gerrit Klaerner.

Yahoo | November 3, 2022

Read More 'TCDA' Stories Here

TCDA Price Returns

1-mo -22.86%
3-mo -98.13%
6-mo -97.56%
1-year -97.20%
3-year -99.48%
5-year N/A
YTD -97.70%
2021 35.60%
2020 -81.32%
2019 60.05%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.66 seconds.